^
Association details:
| Biomarker: | TSG gene expression signature |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Development and validation of a gene expression signature based on RB1, PTEN, and TP53 in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Published date:
02/13/2023
Excerpt:
Overall, 297 pts (baseline characteristics are shown) were included: 125 treated with ADT+Docetaxel...TSGlow signature was independently associated with CPRC-FS (HR 2.66 (95% CI, 1.17 - 6.06), p=0.02) and OS (HR 3.67 (95% CI, 1.33 - 10.10), p=0.012)….A TSGgene expression signature is predictive of taxanes benefit in mHSPC pts and may be useful to personalize the treatment in this setting.
Secondary therapy:
Hormone Therapy
DOI:
10.1200/JCO.2023.41.6_suppl.236